- Review
Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD
- Pratima Dibba,
- Andrew A. Li,
- Brandon J. Perumpail,
- Nimy John,
- Sandy Sallam,
- Neha D. Shah,
- Waiyee Kwong,
- George Cholankeril,
- Donghee Kim and
- Aijaz Ahmed
The two main subsets of nonalcoholic fatty liver disease (NAFLD) include: (1) nonalcoholic fatty liver (NAFL), the more common and non-progressive subtype; and (2) nonalcoholic steatohepatitis (NASH), the less common subtype, which has the potential...

